Decreasing risk of hepatitis A infection in León, Nicaragua: Evidence from cross-sectional and longitudinal seroepidemiology studies

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Mayorga Perez, Orlando ^a   Brinkhof, Martin W G ^b,e   Egger, Matthias ^b   Frösner, Gert ^c   Herzog, Christian ^b,d   Zwahlen, Marcel ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d CRUCELL HOLLAND BV   (Netherlands)

^e SWISS PARAPLEGIC RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; GOOD CLINICAL PRACTICE; HEPATITIS A; HUMAN; INFANT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NICARAGUA; PRESCHOOL CHILD; PROBABILITY; RISK ASSESSMENT; SCHOOL CHILD; SEROEPIDEMIOLOGY; SEROPREVALENCE; SEX DIFFERENCE; SOCIOECONOMICS; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASE CONTROL; CROSS-SECTIONAL STUDIES; EPIDEMIOLOGICAL MONITORING; FEMALE; HEPATITIS A; HEPATITIS A VIRUS; HUMANS; INFANT; LONGITUDINAL STUDIES; MALE; NICARAGUA; PREVALENCE; RISK; YOUNG ADULT;

EID: 84895761119     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087643     Document Type: Article

References (28)

1. World Health Organization (2012) WHO position paper on hepatitis A vaccines - June 2012. Wkly Epidemiol Rec 87: 261-276.
2. World Health Organization (2011) Immunization, Vaccines and Biologicals The Immunological Basis for Immunization Series. Module 18: Hepatitis A. Available: http://whqlibdoc.who.int/publications/2011/9789241501422-eng.pdf. Accessed 2013 Jul 8.
3. Mohd Hanafiah K, Jacobsen KH, Wiersma ST (2011) Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geogr 10:57.
4. Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, et al. (1998) The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination strategies. J Infect Dis 178: 1579-1584. (Pubitemid 28558126)
5. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, et al. (2005) Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294: 202-210. (Pubitemid 41043790)
6. Barkai G, Belmaker I, Givon-Lavi N, Dagan R (2009) The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community. Pediatr Infect Dis J 28: 391-393.
7. Jacobsen KH, Koopman JS (2005) The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns. Int J Epidemiol 34: 600-609. (Pubitemid 40852576)
8. André FE (2006) Universal mass vaccination against hepatitis A. Curr Top Microbiol Immunol 304: 95-114.
9. de Almeida LM, Amaku M, Azevedo RS, Cairncross S, Massad E (2002) The intensity of transmission of hepatitis A and heterogeneities in socio-environmental risk factors in Rio de Janeiro, Brazil. Trans R Soc Trop Med Hyg 96: 605-610. (Pubitemid 36231478)
10. Mayorga Perez O, Herzog C, Zellmeyer M, Loaisiga A, Frösner G, et al. (2003) Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 188: 671-677. (Pubitemid 37115180)
11. Brinkhof MWG, Mayorga O, Bock J, Heininger U, Herzog C (2013) Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels. Vaccine 31: 1490-1495.
12. Keiding N (1991) Age-specific Incidence and Prevalence: a Statistical Perspective. J R Statist Soc 154: 371-412.
13. Laubereau B, Zwahlen M, Neuenschwander B, Heininger U, Schaad UB, et al. (2000) Herpes simplex virus type 1 and 2 in Switzerland. Schweiz Med Wochenschr 130: 143-150. (Pubitemid 30082455)
14. Ades AE, Nokes DJ (1993) Modeling age- and time-specific incidence from seroprevalence: toxoplasmosis. Am J Epidemiol 137: 1022-1034. (Pubitemid 23191069)
15. Ministerio de Salud MINSA (2007) Indicadores Básicos en Salud. Available: http://www.minsa.gob.ni/index.php?option=com-remository&Itemid =52&func=fileinfo&id = 5285. Accessed 2013 Jul 8.
16. Jacobsen KH, Koopman JS (2004) Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 132: 1005-1022. (Pubitemid 39642381)
17. Tanaka J (2000) Hepatitis A shifting epidemiology in Latin America. Vaccine 18 (Suppl 1): S57-S60.
18. Perez OM, Morales W, Paniagua M, Strannegard O (1996) Prevalence of antibodies to hepatitis A, B, C, and E viruses in a healthy population in Leon, Nicaragua. Am J Trop Med Hyg 55: 17-21.
19. Wasley A, Fiore A, Bell BP (2006) Hepatitis A in the era of vaccination. Epidemiol Rev 28: 101-111. (Pubitemid 44289093)
20. van Damme P, Van Herck K (2005) Effect of hepatitis A vaccination programs. JAMA 294: 246-248.
21. Quezada A, Baron-Papillon F, Coudeville L, Maggi L (2008) Universal vaccination of children against hepatitis A in Chile: a cost-effectiveness study. Rev Panam Salud Publica 23: 303-312.
22. Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J (2007) The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. J Gastroenterol 42: 152-160. (Pubitemid 46404220)
23. Victor JC, Surdina TY, Suleimenova SZ, Favorov MO, Bell BP, et al. (2006) Person-to-person transmission of hepatitis A virus in an urban area of intermediate endemicity: implications for vaccination strategies. Am J Epidemiol 163: 204-210. (Pubitemid 43145746)
24. Sartori AM, de Soárez PC, Novaes HM, Amaku M, de Azevedo RS, et al (2012) Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context. Vaccine 30: 7489-7497.
25. Pichichero ME (2009) Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics 124:1633-1641.
26. Vizzotti C, González J, Gentile A, Rearte A, Ramonet M, et al. (2014) Impact of the single dose immunization strategy against hepatitis A in Argentina. Ped Infect Dis J 33: 84-88.
27. World Health Organization (2012) Meeting of the Strategic Advisory Group of Experts on immunization, April 2012 - conclusions and recommendations. Wkly Epid Rec 87: 201-216.
28. Ott JJ, Wiersma ST (2013) Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. Int J Infect Dis 17:e939-e944.